Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

Table 1

Characteristics of the trials included.

Study	Journal	Publication year	No. of centers	No.of patients	Patients	Randomization	Types of stent	Time of abciximab	Follow-up duration
Antoniucci et al. [27]	JACC	2003	—	400	With CS	Abciximab (n = 200) vs. placebo (n = 200)	BMS	Before PCI	30 days 6 months
Brener et al. [22]	Circulation	1998	36	483	No CS	Abciximab (n = 241) vs. placebo (n = 242)	BMS	Before angiography	30 days 6 months
Ernst et al. [23]	JACC	2004	Single-center	119	No CS	Abciximab (n = 30) vs. placebo (n = 89)	—	Before PCI	In-hospital 30 days
Mehilli et al. [24]	Circulation	2009	5	800	No CS	Abciximab (n = 401) vs. placebo (n = 399)	BMS DES	Before angiography	30 days
Montalescot et al. [4]	N Engl J Med	2001	26	300	With CS	Abciximab (n = 149) vs. placebo (n = 151)	BMS	Before angiography	30 days 6 months
Neumann et al. [25]	Circulation	1998	—	200	—	Abciximab (n = 102) vs. placebo (n = 98)	BMS	—	14 days 30 days
Neumann et al. [3]	JACC	2000	—	401	—	Abciximab (n = 201) vs. placebo (n = 200)	BMS	—	30 days 1 year
Petronio et al. [28]	Am Heart J	2005	—	60	No CS	Abciximab (n = 30) vs. placebo (n = 30)	BMS	Before PCI	30 days 6 months
Tcheng et al. [26]	Circulation	2003	76	2082	No CS	Abciximab (n = 1052) vs. placebo (n = 1030)	BMS	—	30 days 1 year
Zorman et al. [29]	Am J Cardiol	2002	—	163	With CS	Abciximab (n = 112) vs. placebo (n = 51)	BMS	Both	In-hospital 6 months

CS: cardiac shock; BMS: bare-metal stent; DES: drug-eluting stent; PCI, percutaneous coronary intervention.